As the gene therapy revolution starts coming to fruition, new challenges are emerging.
Scaling up manufacturing at a time when hundreds of therapies are advancing has strained capacity and created shortages in the supply chain. Recent FDA actions are raising questions about its regulatory requirements. And all the usual hurdles to developing and launching new treatments still apply. Join us to learn how companies are navigating manufacturing, regulatory requirements and scientific breakthroughs—and what’s being done industry-wide to smooth the path to market.